青少年和年轻成人接种COVID-19疫苗后疑似心肌炎的临床过程与短期结局
该研究回顾性收集了2021年7月4日前接种COVID-19疫苗后30天内出现疑似心肌炎的<21岁患者数据,共纳入139例患者(140次发作),其中49例确诊、91例可能。大多数病例在mRNA疫苗接种后发生,临床症状轻微,胸痛最常见,心脏MRI异常发现常见,但短期随访左室功能恢复正常,无死亡。
要点
- 接种COVID-19疫苗后疑似心肌炎多见于男性青少年,多在第二剂mRNA疫苗后2天左右出现胸痛。
- 多数患者临床过程轻微,住院时间短,未出现需要ECMO或死亡的情况。
- 心脏MRI异常发现常见,包括晚钆增强和心肌水肿,但短期左室功能多可恢复。
核心结论
- 大多数<21岁人群接种COVID-19疫苗后发生的疑似心肌炎临床过程轻微,症状迅速缓解,短期结局良好。
研究设计与样本
- 回顾性多中心研究,纳入26个中心、139例<21岁、接种COVID-19疫苗后30天内疑似心肌炎的患者,共140次发作。
主要发现
- 139例患者中49例为确诊心肌炎,91例为可能心肌炎;126例(90.6%)为男性,中位年龄15.8岁。
- 136例(97.8%)在mRNA疫苗接种后发生,131例(94.2%)为辉瑞-BioNTech疫苗,128例(91.4%)在第二剂后发生。
- 症状开始中位时间为接种后2天(范围0-22,IQR 1-3),最常见的症状是胸痛(99.3%)。
- 26例(18.7%)入住ICU,2例接受正性肌力/血管活性药物支持,无患者需要ECMO或死亡;中位住院时间2天(范围0-10,IQR 2-3)。
- 97例患者接受心脏MRI检查,其中75例(77.3%)有异常发现:74例(76.3%)晚钆增强,54例(55.7%)心肌水肿,49例(50.5%)符合Lake Louise标准。
关键数值与推荐
- 心肌炎确诊或可能分类基于美国疾病控制与预防中心的定义。
- 心脏MRI findings采用Lake Louise标准。
- 超声心动图显示左室射血分数<55%的26例患者中,有随访的25例均恢复正常功能。
临床怎么用
- 对于接种COVID-19疫苗后出现胸痛的青少年,应考虑疑似心肌炎并进行心电图、肌钙蛋白和心脏MRI评估。
- 多数患者症状轻微且短期预后良好,可进行保守治疗和对症处理。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 缺乏长期随访数据,无法评估远期结局。
- 未设置对照组,无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the clinical course and short-term outcomes of suspected myocarditis after the coronavirus disease 2019 (COVID-19) vaccination has important public health implications in the decision to vaccinate youth. METHODS: We retrospectively collected data on patients <21 years old presenting before July 4, 2021, with suspected myocarditis within 30 days of COVID-19 vaccination. Lake Louise criteria were used for cardiac MRI findings. Myocarditis cases were classified as confirmed or probable on the basis of the Centers for Disease Control and Prevention definitions. RESULTS: We report on 139 adolescents and young adults with 140 episodes of suspected myocarditis (49 confirmed, 91 probable) at 26 centers. Most patients were male (n=126, 90.6%) and White (n=92, 66.2%); 29 (20.9%) were Hispanic; and the median age was 15.8 years (range, 12.1-20.3; interquartile range [IQR], 14.5-17.0). Suspected myocarditis occurred in 136 patients (97.8%) after the mRNA vaccine, with 131 (94.2%) after the Pfizer-BioNTech vaccine; 128 (91.4%) occurred after the second dose. Symptoms started at a median of 2 days (range, 0-22; IQR, 1-3) after vaccination. The most common symptom was chest pain (99.3%). Patients were treated with nonsteroidal anti-inflammatory drugs (81.3%), intravenous immunoglobulin (21.6%), glucocorticoids (21.6%), colchicine (7.9%), or no anti-inflammatory therapies (8.6%). Twenty-six patients (18.7%) were in the intensive care unit, 2 were treated with inotropic/vasoactive support, and none required extracorporeal membrane oxygenation or died. Median hospital stay was 2 days (range, 0-10; IQR, 2-3). All patients had elevated troponin I (n=111, 8.12 ng/mL; IQR, 3.50-15.90) or T (n=28, 0.61 ng/mL; IQR, 0.25-1.30); 69.8% had abnormal ECGs and arrhythmias (7 with nonsustained ventricular tachycardia); and 18.7% had left ventricular ejection fraction <55% on echocardiogram. Of 97 patients who underwent cardiac MRI at a median 5 days (range, 0-88; IQR, 3-17) from symptom onset, 75 (77.3%) had abnormal findings: 74 (76.3%) had late gadolinium enhancement, 54 (55.7%) had myocardial edema, and 49 (50.5%) met Lake Louise criteria. Among 26 patients with left ventricular ejection fraction <55% on echocardiogram, all with follow-up had normalized function (n=25). CONCLUSIONS: Most cases of suspected COVID-19 vaccine myocarditis occurring in persons <21 years have a mild clinical course with rapid resolution of symptoms. Abnormal findings on cardiac MRI were frequent. Future studies should evaluate risk factors, mechanisms, and long-term outcomes.
引用
- Truong DT, Dionne A, Muniz JC, et al. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. Circulation. 2021. PMID: 34865500. doi:10.1161/CIRCULATIONAHA.121.056583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。